Rapid diagnosis of onchocerciasis using urinary biomarkers
使用尿液生物标志物快速诊断盘尾丝虫病
基本信息
- 批准号:MR/P025307/1
- 负责人:
- 金额:$ 77.34万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2017
- 资助国家:英国
- 起止时间:2017 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Onchocerciasis or river blindness is a parasitic disease affecting 17 million in sub-Saharan Africa. It causes visual impairment, sometimes leading to irreversible blindness, and intense itching of the skin. The symptoms of the disease can be controlled by annual treatment with the drug ivermectin, which kills the larval stages in the skin, but the adult worms are not eliminated and can survive for more than 10 years.Diagnosis of the disease has been dependent for many decades on microscopic examination of skin snips for the larval stage. This is a painful procedure that, not surprisingly, is being met with reduced compliance in communities that have been sampled repeatedly over many years.In this proposal, we aim to radically improve the diagnosis of onchocerciasis by testing for the presence of adult worms using a patient's urine sample. We have discovered that the worms release proteins and small RNA molecules into urine that can be detected by mass spectrometers and sequencing technology. The molecules are associated with small "packets" called extracellular vesicles. We will isolate these vesicles from urine samples to identify the best markers for the disease. To facilitate the process, we will also test urine samples from African cattle, which are infected with a parasite very closely related to that which causes human onchocerciasis. By treating the cattle with drugs that kill the adult parasites, we will test whether the molecules released in urine are a good indicator of whether live worms remain in the host's body. This is a particularly important at the present time, as several drugs with potential activity against adult worms are being tested in clinical trials in humans, and currently the only way to know whether the worms have been killed is to perform surgery on the volunteers.In the final stages of the proposal, we will investigate methods to capture parasite molecules from urine in an efficient manner. This will be necessary to move away from a diagnostic test that is dependent on expensive laboratory equipment to a kit that ultimately could be used in rural Africa.
盘尾丝虫病或河盲症是一种寄生虫病,影响撒哈拉以南非洲的1 700万人。它会导致视力障碍,有时会导致不可逆转的失明,以及皮肤的剧烈瘙痒。这种疾病的症状可以通过每年使用药物伊维菌素来控制,伊维菌素可以杀死皮肤中的幼虫阶段,但蠕虫不能被消灭,可以存活10年以上。几十年来,这种疾病的诊断一直依赖于对幼虫阶段的皮肤切片进行显微镜检查。这是一个痛苦的过程,毫不奇怪,在多年来反复采样的社区中,遵守率降低。在这项提案中,我们的目标是通过使用患者的尿液样本检测蠕虫的存在来从根本上改善盘尾丝虫病的诊断。我们已经发现,蠕虫释放蛋白质和小RNA分子到尿液中,可以通过质谱仪和测序技术检测到。这些分子与称为细胞外囊泡的小“包”相关联。我们将从尿样中分离这些囊泡,以确定该疾病的最佳标记。为了促进这一进程,我们还将检测非洲牛的尿液样本,这些牛感染了一种与引起人类盘尾丝虫病的寄生虫非常密切相关的寄生虫。通过用杀死成虫寄生虫的药物治疗牛,我们将测试尿液中释放的分子是否是活蠕虫是否留在宿主体内的良好指标。这一点在目前尤为重要,因为几种对成虫具有潜在活性的药物正在人体临床试验中进行测试,目前唯一知道蠕虫是否已被杀死的方法是对志愿者进行手术。在提案的最后阶段,我们将研究以有效方式从尿液中捕获寄生虫分子的方法。这对于从依赖昂贵实验室设备的诊断测试转向最终可在非洲农村使用的工具包是必要的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Benjamin Makepeace其他文献
Obituary: Siv Aina Jensen Leendertz (Born Siv Aina Jensen: 1973–2018)
- DOI:
10.1007/s10764-018-0071-5 - 发表时间:
2018-11-20 - 期刊:
- 影响因子:1.800
- 作者:
Chantal Akoua-Koffi;Sandra Beermann;Sébastien Calvignac-Spencer;Emmanuel Couacy-Hymann;Helene De Nys;Bernhard Ehlers;Thomas Gillespie;Jeffrey Gilbert;Jan F. Gogarten;Sandra J. Laney;Felix Lankester;Fabian H. Leendertz;Benjamin Makepeace;Andreas Nitsche;Georg Pauli;Maude Pauly;Eystein Skjerve;Daniel Stern;Roma Thamm;Dominic Travis;Steve Unwin;Roman Wittig;Livia Wittiger - 通讯作者:
Livia Wittiger
Benjamin Makepeace的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Benjamin Makepeace', 18)}}的其他基金
The Tick Cell Biobank - a UK and international biological resource
Tick Cell Biobank - 英国和国际生物资源
- 批准号:
BB/P024270/1 - 财政年份:2017
- 资助金额:
$ 77.34万 - 项目类别:
Research Grant
GCRF-BBR: The Tick Cell Biobank: outposts in Asia, Africa and South America
GCRF-BBR:蜱细胞生物库:亚洲、非洲和南美洲的前哨站
- 批准号:
BB/P024378/1 - 财政年份:2017
- 资助金额:
$ 77.34万 - 项目类别:
Research Grant
相似国自然基金
均相液相生物芯片检测系统的构建及其在癌症早期诊断上的应用
- 批准号:82372089
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
环境抗雄激素干预AR/TGFB1I1致尿道下裂血管内皮细胞发育异常的机制及其“预警信号”在早期诊断中的价值
- 批准号:82371605
- 批准年份:2023
- 资助金额:46.00 万元
- 项目类别:面上项目
基于密度泛函理论金原子簇放射性药物设计、制备及其在肺癌诊疗中的应用研究
- 批准号:82371997
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
基于质谱贴片的病原菌标志物检测及伤口感染诊断应用
- 批准号:82372148
- 批准年份:2023
- 资助金额:60.00 万元
- 项目类别:面上项目
人脑胶质瘤Aurora A基因作用及其分子机制的研究
- 批准号:81072082
- 批准年份:2010
- 资助金额:33.0 万元
- 项目类别:面上项目
制冷系统故障诊断关键问题的定量研究
- 批准号:50876059
- 批准年份:2008
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
Development of an ELISA for serosurveillance of human hookworm
开发用于人类钩虫血清监测的 ELISA
- 批准号:
10697222 - 财政年份:2023
- 资助金额:
$ 77.34万 - 项目类别:
First-in-class, highly sensitive and specific rapid diagnostic test to detect Paragonimus infections
用于检测并殖吸虫感染的一流、高灵敏度和特异性的快速诊断测试
- 批准号:
10545410 - 财政年份:2022
- 资助金额:
$ 77.34万 - 项目类别:
Discovery and characterization of ocular regulatory elements through evolutionary analysis
通过进化分析发现和表征眼部调节元件
- 批准号:
10927633 - 财政年份:2020
- 资助金额:
$ 77.34万 - 项目类别:
Repeat Ivermectin Mass Drug Administrations for MALaria control II (RIMDAMAL II): a double-blind cluster randomized trial for integrated control of malaria
重复伊维菌素大规模药物管理用于疟疾控制 II (RIMDAMAL II):疟疾综合控制的双盲整群随机试验
- 批准号:
9754784 - 财政年份:2018
- 资助金额:
$ 77.34万 - 项目类别:
Repeat Ivermectin Mass Drug Administrations for MALaria control II (RIMDAMAL II): a double-blind cluster randomized trial for integrated control of malaria
重复伊维菌素大规模药物管理用于疟疾控制 II (RIMDAMAL II):疟疾综合控制的双盲整群随机试验
- 批准号:
10468728 - 财政年份:2018
- 资助金额:
$ 77.34万 - 项目类别:
Repeat Ivermectin Mass Drug Administrations for MALaria control II (RIMDAMAL II): a double-blind cluster randomized trial for integrated control of malaria
重复伊维菌素大规模药物管理用于疟疾控制 II (RIMDAMAL II):疟疾综合控制的双盲整群随机试验
- 批准号:
10223135 - 财政年份:2018
- 资助金额:
$ 77.34万 - 项目类别:
IMPROVED ANTIGEN DETECTION TESTS FOR FILARIAL INFECTIONS
改进丝虫感染的抗原检测测试
- 批准号:
9509332 - 财政年份:2016
- 资助金额:
$ 77.34万 - 项目类别:
IMPROVED ANTIGEN DETECTION TESTS FOR FILARIAL INFECTIONS
改进丝虫感染的抗原检测测试
- 批准号:
9180411 - 财政年份:2016
- 资助金额:
$ 77.34万 - 项目类别: